As distinct cancer biomarkers have been discovered in recent years, a need to reclassify
tumors by more than their histology has been proposed, and therapies are now tailored to …

Endocytosis is a complex process whereby cell surface proteins, lipids and fluid from the
extracellular environment are packaged, sorted and internalized into cells. Endocytosis is …

Antibody–drug conjugates (ADCs) have become a credentialled class of anticancer drugs
for both solid and hematological malignancies, with regulatory approvals mainly as single …

Background Low human epidermal growth factor receptor 2 (HER2) expression is emerging
as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 …

Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of
this disease. This Series article reviews the main achievements so far in the treatment of …

Purpose Human epidermal growth factor receptor 2 (HER2, ERBB2)–activating mutations
occur in 2% of lung cancers. We assessed the activity of ado-trastuzumab emtansine, a …

Targeted protein degradation using the PROTAC technology is emerging as a novel
therapeutic method to address diseases driven by the aberrant expression of a disease …

Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …

Amplification of and oncogenic mutations in ERBB2, the gene encoding the HER2 receptor
tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate …

ERBB receptors were linked to human cancer pathogenesis approximately three decades
ago. Biomedical investigators have since developed substantial understanding of the …